Abstract: Cervical cancer is the most common reproductive system malignancy in women. Its primary cause is persistent infection with high-risk human papillomavirus. Traditional treatment methods include surgery, radiotherapy, and chemotherapy, but the prognosis for advanced cervical cancer remains dismal. In recent years, therapeutic vaccines, immune checkpoint inhibitors, adoptive T cell therapy, and other immunotherapies have been widely used in cervical cancer, notably improving patient survival. This article reviews clinical trials and recent advances in immunotherapy for in locally advanced cervical cancer (LACC).